A Prospective Study of Socioeconomic Status, Prostate Cancer Screening and Incidence Among Men at High Risk for Prostate Cancer
Overview
Public Health
Authors
Affiliations
Purpose: Higher socioeconomic status (SES) men are at higher risk of prostate cancer (PCa) diagnosis, an association commonly interpreted as a function of higher rates of prostate screening among higher SES men. However, the extent to which screening explains this association has not been well quantified.
Methods: Within a Detroit area cohort of 6,692 men followed up after a benign prostate procedure, a case-control study was conducted of 494 PCa cases and controls matched on age, race, duration of follow-up, and date of initial benign finding; 2000 Census data were used in a principal component analysis to derive a single factor, labeled the neighborhood SES index (NSESI), representing zip code-level SES.
Results: Among cases, higher SES was associated with a younger age at initial biopsy: -1.48 years (95 % CI, -2.32, -0.64) per unit NSESI. After adjustment for confounders and duration of follow-up, higher SES was associated with more PSA tests and DRE during follow-up; 9 % (95 % CI, 2, 16) and 8 % (95 % CI, 1, 15) more respectively, per unit NSESI. Higher SES was associated with a higher risk of PCa diagnosis during follow-up, multivariable adjusted OR = 1.26 per unit increase in NSESI (95 % CI, 1.04, 1.49). Further adjustment for screening frequency somewhat reduced the association between SES and PCa risk (OR = 1.19 per unit NSESI, 95 % CI, 0.98, 1.44).
Conclusions: Differences in screening frequency only partially explained the association between higher zip code SES and PCa risk; other health care-related factors should also be considered as explanatory factors.
Wang Z, Wang C, Gou X, Pei L, Qiao X Sci Rep. 2025; 15(1):4639.
PMID: 39920261 PMC: 11806085. DOI: 10.1038/s41598-025-88300-0.
Screening for prostate cancer: evidence, ongoing trials, policies and knowledge gaps.
Bratt O, Auvinen A, Arnsrud Godtman R, Hellstrom M, Hugosson J, Lilja H BMJ Oncol. 2025; 2(1):e000039.
PMID: 39886507 PMC: 11203092. DOI: 10.1136/bmjonc-2023-000039.
Hiyoshi A, Alexanderson K, Tinghog P, Cao Y, Fall K, Montgomery S Cancer. 2024; 131(1):e35580.
PMID: 39377486 PMC: 11694158. DOI: 10.1002/cncr.35580.
Pichardo C, Ezeani A, Pichardo M, Agurs-Collins T, Powell-Wiley T, Ryan B Cancer Med. 2023; 13(1):e6828.
PMID: 38151903 PMC: 10807554. DOI: 10.1002/cam4.6828.
Reduced Racial Disparity as a Result of Survival Improvement in Prostate Cancer.
Zhang B, Li J, Tang M, Cheng C Cancers (Basel). 2023; 15(15).
PMID: 37568792 PMC: 10417437. DOI: 10.3390/cancers15153977.